Clinical application of this technology is reported for HSV1-tk-transduced CAR-T cells engineered to express an interleukin-13 (IL-13) zetakine, which targets IL-13 receptor alpha 2-expressing glioblastoma (69, 120, 121). The gene discussed is IL13; the disease is glioblastoma.